Clinical trial
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With…
NCT00201812 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00201812 |
|---|---|
| Title | Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors |
| Official title | Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | Immunex Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Etanercept, Docetaxel, Dexamethasone |
| Enrollment | 27 |
| Start date | Nov 1, 2000 |
| Primary completion | Jan 1, 2004 |
| Completion | May 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: